The primary composite outcome of time to CV death, non-fatal MI, and non-fatal stroke occurred significantly less in the GLP-1 receptor agonist group compared to placebo (13 vs. 14.9%, p = 0.01 for superiority). Here, GLP1R is linked to stroke disorder.